Novo nordisk as
NVO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，股利評分名列前茅，值得長期累積部位。若想獲得較好的進場時機，可參考技術面趨勢與波段評分
NVO 近期報酬表現
-0.29%
Novo nordisk as
0.54%
同產業平均
-0.46%
S&P500
與 NVO 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
LLY | Eli lilly and company | 4 分 | 3 分 | 2 分 | 3 分 | 5 分 | |
GMAB | Genmab a/s | 5 分 | 1 分 | 2 分 | 1 分 | 1 分 | |
GSK | Gsk plc | 3 分 | 5 分 | 1 分 | 2 分 | 5 分 | |
ZTS | Zoetis inc | 5 分 | 1 分 | 1 分 | 3 分 | 3 分 | |
PFE | Pfizer inc | 3 分 | 1 分 | 2 分 | 2 分 | 5 分 |
- LLY Eli lilly and company價值 4 分趨勢 3 分波段 2 分籌碼 3 分股利 5 分查看更多
NVO 公司資訊
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.